通化金马(000766) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥319,407,464.84, an increase of 1.16% year-on-year, while the revenue for the year-to-date period decreased by 7.24% to ¥968,589,176.59[3] - Net profit attributable to shareholders for Q3 2024 reached ¥11,455,406.85, a significant increase of 139.97% compared to the same period last year, with a year-to-date increase of 53.84% to ¥23,923,749.83[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥9,986,437.35 for Q3 2024, up 218.77% year-on-year, and increased by 51.15% year-to-date to ¥16,387,813.37[3] - Basic and diluted earnings per share for Q3 2024 were both ¥0.0119, reflecting a 142.86% increase compared to the same period last year[3] - Total operating revenue for Q3 2024 was CNY 968,589,176.59, a decrease of 7.25% from CNY 1,044,242,077.32 in the same period last year[12] - Net profit for Q3 2024 was CNY 23,864,656.74, an increase of 60.66% compared to CNY 14,851,915.32 in Q3 2023[14] - Earnings per share for Q3 2024 were CNY 0.0248, up from CNY 0.0161 in the previous year[14] Assets and Liabilities - The company's total assets as of the end of Q3 2024 were ¥4,597,798,178.74, representing a 1.74% increase from the end of the previous year[4] - As of September 30, 2024, the total assets of Tonghua Jinma Pharmaceutical Group reached CNY 4,597,798,178.74, an increase from CNY 4,519,244,365.23 at the beginning of the period, reflecting a growth of approximately 1.2%[11] - Total liabilities as of Q3 2024 were CNY 2,255,806,343.71, compared to CNY 2,201,117,186.94 at the end of the previous year[12] - The total liabilities of the company increased, with accounts payable decreasing to CNY 128,515,605.73 from CNY 183,349,577.55, indicating a reduction of approximately 30%[11] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥111,407,499.68, an increase of 31.01% compared to the same period last year[5] - The net cash flow from operating activities for Q3 2024 was ¥111,407,499.68, an increase from ¥85,035,967.09 in Q3 2023, representing a growth of approximately 31.5%[16] - The total cash inflow from financing activities was ¥242,070,003.26, compared to ¥130,000,000.00 in the same period last year, indicating an increase of 86.0%[16] - The net cash flow from investing activities was -¥26,147,171.68, a significant decrease from ¥83,292,448.53 in Q3 2023, reflecting a decline of approximately 131.4%[16] - The cash inflow from operating activities totaled ¥994,484,220.29, compared to ¥1,052,761,627.96 in the previous year, indicating a decrease of about 5.5%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 49,247, with the largest shareholder holding 19.66% of the shares[8] - Total equity attributable to shareholders of the parent company was CNY 2,341,586,669.39, an increase from CNY 2,317,662,919.56 year-over-year[12] Operational Metrics - The company's cash and cash equivalents increased by 55.40% to ¥275,742,281.02 due to increased financing activities[5] - Accounts receivable decreased to CNY 483,372,335.19 from CNY 496,821,395.71, showing a decline of approximately 2.7%[11] - Inventory increased to CNY 403,106,130.85 from CNY 369,169,011.48, representing an increase of about 9.2%[11] - Research and development expenses for Q3 2024 were CNY 28,499,623.60, slightly down from CNY 29,740,704.07 in the same period last year[13] - The company reported a decrease in sales expenses to CNY 525,253,917.92 from CNY 584,625,189.02 in the previous year[13]